The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Will Be The Estimated Market Valuation Of The Ranibizumab Market By The End Of 2030?
The ranibizumab market has experienced consistent expansion in recent years. It is projected to increase from $2.76 billion in 2025 to $2.87 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.0%. The growth observed in the historical period can be attributed to several factors, including the rising prevalence of age-related macular degeneration, clinical validation of anti-VEGF therapy’s effectiveness, an increasing incidence of diabetic retinopathy, enhancements in diagnostic imaging for retinal disorders, and prompt regulatory approvals for ranibizumab.
The ranibizumab market size is projected to experience consistent expansion over the coming years, reaching $3.31 billion by 2030, with a compound annual growth rate (CAGR) of 3.6%. This anticipated growth during the forecast period is largely driven by an expanding global aging population, increasing diabetes prevalence worldwide, broader access to advanced ophthalmic care, a rise in the adoption of intravitreal injections, and continuous improvements in retinal disease screening programs. Key developments anticipated during this period involve the increasing adoption of anti-vegf therapies for retinal diseases, a growing preference for prefilled syringe formulations, escalating treatment demand for diabetic eye disorders, the expansion of ophthalmology specialty care centers, and a greater reliance on long-term maintenance therapy in chronic retinal conditions.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16172&type=smp
What Major Growth Drivers Are Shaping The Outlook Of The Ranibizumab Market?
The rising occurrence of ocular conditions is projected to propel the expansion of the ranibizumab market in the future. Ocular conditions cover a spectrum of ailments affecting the eyes, potentially compromising vision and eye health. The growing incidence of eye diseases is attributed to elements like aging populations and lifestyle shifts, alongside an increase in chronic illnesses such as diabetes. Ranibizumab is utilized for treating conditions like age-related macular degeneration and diabetic retinopathy, thereby assisting in mitigating vision impairment within the context of the increasing prevalence of eye diseases. For instance, in August 2023, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately 2.2 billion people worldwide experience either near or distance vision impairment. Therefore, the expanding prevalence of eye diseases will stimulate the growth of the ranibizumab market.
Which Segment Classifications Shape The Ranibizumab Market?
The ranibizumab market covered in this report is segmented –
1) By Product: Single Use Prefilled Syringe, Single Use Glass Vial
2) By Application: Wet Age Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Myopic Choroidal Neovascularization (MCNV), Retinal Vein Occlusion (RVO)
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Single Use Prefilled Syringe: 0.3 Ml Syringe, 0.5 Ml Syringe, 1 Ml Syringe, Other Volume Variants
2) By Single Use Glass Vial: 0.5 Mg Or 0.05 Ml Vial, 1.0 Mg Or 0.1 Ml Vial, 2.0 Mg Or 0.2 Ml Vial, Other Volume Variants
How Are Trends Impacting The Ranibizumab Market?
Companies active in the ranibizumab market are prioritizing economical therapeutic options, such as ranibizumab biosimilars, to address and prevent vision impairment in individuals with retinal conditions. A ranibizumab biosimilar is a biological medicine closely resembling the reference ranibizumab product, yet sold under an alternative brand, presenting a more budget-friendly choice while delivering comparable efficacy and safety profiles. For example, in April 2024, Formycon AG, a German biotechnology firm, and Bioeq AG, a Swiss biopharmaceutical entity, announced the commercial introduction of FYB201, a biosimilar to Lucentis (Ranibizumab), across Canada and Switzerland. This launch occurred subsequent to marketing approvals granted by Health Canada, utilizing the brand name Ranopto, and Swissmedic, under the brand name Ranivisio. FYB201 offers a novel, superior quality, potent, and reasonably priced treatment pathway for patients afflicted with severe retinal ailments. Its significance as a cost-effective treatment alternative for patients in the USA and various European regions has already been demonstrated.
Which Companies Are Expanding Their Footprint In The Ranibizumab Market?
Major companies operating in the ranibizumab market are F. Hoffmann-La Roche AG, Genentech Inc., Bayer AG, Novartis AG, Biocon Limited, Samsung Biologics Co Ltd, Celltrion Healthcare Co Ltd, Formycon AG, Coherus BioSciences Inc, Xbrane Biopharma AB, Alvotech, Stada Arzneimittel AG, Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd, Enzene Biosciences Ltd, Amman Pharmaceutical Industries
Read the full ranibizumab market report here:
https://www.thebusinessresearchcompany.com/report/ranibizumab-global-market-report
Which Regions Are Projected To Dominate The Ranibizumab Market In The Coming Years?
North America was the largest region in the ranibizumab market in 2025. The regions covered in the ranibizumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Ranibizumab Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=16172&type=smp
Browse Through More Reports Similar to the Global Ranibizumab Market 2026, By The Business Research Company
Ranibizumab Market Report 2026
https://www.thebusinessresearchcompany.com/report/ranibizumab-global-market-report
Ibrutinib Market Report 2026
https://www.thebusinessresearchcompany.com/report/ibrutinib-global-market-report
Takaful Market Report 2026
https://www.thebusinessresearchcompany.com/report/takaful-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model